MedTrace Logo

Modified Release Posaconazole in Patients With Cystic Fibrosis

NCT03421366 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-10-26

No results posted yet for this study

Summary

A prospective single center observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formulation, can be achieved.

Conditions

Interventions

DRUG

Posaconazole

A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients

Sponsors & Collaborators

  • Bayside Health

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2021-02-05
Completion
2021-02-05
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03421366 on ClinicalTrials.gov